TRIAL TO ASSESS CHELATION THERAPY (TACT)

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Coronary heart disease (CHD) is the leading cause of premature morbidity and mortality in the U.S.. Currently proven treatments for CHD include lifestyle modification, drugs, and procedures. Despite the availability of these treatments, many patients seek out and receive alternative therapies, including the complementary and alternative medicine (CAM) practice called chelation therapy. Chelation therapy involve IV administration of disodium ethylenediaminetetraacetic acid (EDTA), combined with high dose antioxidant vitamin and mineral supplements. Thus, clinical benefit from chelation therapy, if seen, could be due to EDTA, antioxidants, mineral supplements, or a combination of these. The purpose of this large scale 5-year multi-center trial is: 1) to determine whether chelation or high dose supplements in patients with CHD reduces the incidence of clinical cardiovascular events; 2) to determine whetner chelation and high-dose supplements have acceptable safety profiles; 3) To determine whether chelation or high-dose supplements improve the quality of life; 4) To conduct an economic analysis of chelation therapy and high dose supplements.